Travere Therapeutics (NASDAQ:TVTX) had its "neutral" rating reaffirmed by analysts at Piper Sandler.
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit [Yahoo! Finance]
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? [Yahoo! Finance]
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm